Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2023

Name: Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2023
SKU: 4753
Availability: InStock

$30.00

This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!

Categories: Cardiology, Internal Medicine Tags: CARDIOLOGY, git

Description

Course Overview

Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2023 Despite notable advances in management, atherosclerotic cardiovascular disease (ASCVD) and its major clinical manifestations remains a leading cause of both morbidity and mortality worldwide. In the United States alone, ASCVD is the leading cause of death in most racial and ethnic populations and is estimated to cost more than $200 billion per year due to medications, healthcare service utilization, and productivity losses.

Many of these human and economic costs are largely attributable to poor implementation of prevention strategies in adults and failure to control ASCVD risk factors using available medications and lifestyle interventions. The Scripps Cardiovascular Atherosclerosis conference is designed to assist clinicians in the prevention, diagnosis, treatment, and ongoing management of ASCVD among patients in their clinical practices as well as to promote increased awareness of prudent lifestyle and dietary choices to improve patient outcomes.

Description

+ Include: 13 videos + 1 pdf, size: 2.36 GB

+ Target Audience: cardiologist, endocrinologists, internists

Educational Objectives

After attending this live activity, participants should be able to:

Discuss the principles and applications of personalized medicine and genomics in the management of atherosclerotic cardiovascular disease.
Describe the latest advances in the management of hypertension and its impact on atherosclerotic cardiovascular disease.
Assess the role of glucagon-like peptide-1 (GLP-1) agonists in the pharmacotherapy of obesity and type 2 diabetes.
Evaluate the role of high-sensitivity troponin in risk assessment, including its use in combination with other clinical and laboratory assessments.
Explain the role of health care providers in the implementation and interpretation of genetic testing results for familial hypercholesterolemia.
Apply the latest guidelines for the diagnosis and treatment of dyslipidemia, including the use of lipid-lowering therapy.
Assess the impact of new and emerging lipid-lowering agents on patient outcomes.
Cite the latest guidelines and evidence-based recommendations for the selection of therapies for individual patients with heart failure.
Determine the potential role of supplements in the primary and secondary prevention of atherosclerotic cardiovascular disease.
Describe current principles and applications of non-invasive coronary evaluations, including computed tomography (CT) coronary artery imaging.
Summarize the latest information regarding nonalcoholic fatty liver disease, including epidemiology, pathophysiology and contribution to cardiovascular disease.
Analyze data regarding the effects of testosterone on the cardiovascular system and the risk of cardiovascular disease in men receiving testosterone therapy.

Target Audience

Cardiologists
Endocrinologists
Internists
General Practitioners
Nurses, Nurse Practitioners, Physician Assistants

Topics:

brochure_lipids23_compressed.pdf
Advanced Hypertension Management.mp4
Bio-Identical Hormones and Testosterone Supplementation.mp4
Evaluate Horrible Cholesterol, Lipoprotein A Prevalence, Impact, and Novel Therapeutics.mp4
Genetic Testing for Familial Hypercholesterolemia When to Test, Whom to Test.mp4
New Concepts in Dyslipidemia Dispelling 10 Truths About Lipids.mp4
Non-HDL Targets for Risk Reduction.mp4
Nonalcoholic Fatty Liver Disease and Its Contribution to CV Disease.mp4
Obesity and Diabetic Pharmacotherapy Are You Ready for GLP-1 Agonists.mp4
Panel Discussion Q&A 1.mp4
Panel Discussion Q&A 2.mp4
Panel Discussion Q&A 3.mp4
Panel Discussion Q&A 4.mp4
Supplements in Primary and Secondary Prevention of ASCVD.mp4